Skip to content
Screener

Allogene Therapeutics ALLO Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue-
EPS-$0.19Beat by $0.04
EPS estimate-$0.23

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.5K
EPS estimate-$0.13

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$44.9M+37.4%
Net income-$41.4M+37.5%
EPS (diluted)-$0.19+40.6%

Balance sheet

See full
Cash & equivalents$48.1M-21.8%
Total debt$85.1M-8.0%
Total equity$315.3M-32.0%
Total assets$439.8M-25.4%

Cash flow

See full
Operating cash flow-$29.7M+32.7%
CapEx$243.0K-43.4%
Free cash flow-$29.9M+32.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$275.13M-53.0%
Enterprise value$312.17M-49.4%

Returns & leverage

See full
Return on equity-54.4%+0.2pp
Debt / equity0.3×+0.1×
Current ratio8.2×-1.2×

Segments

By segment

See full
Reportable Segment-—

FAQ

When did Allogene Therapeutics report Q3 2025 earnings?
Allogene Therapeutics (ALLO) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Allogene Therapeutics's Q3 2025 revenue and EPS?
Allogene Therapeutics reported revenue of - and eps of $-0.19 for Q3 2025.
Did Allogene Therapeutics beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.23 by $0.04.
How did Allogene Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 29.6% from $-0.27.
Where can I find Allogene Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-050227) and the 10-Q periodic report (0001628280-25-050230) directly on SEC EDGAR. The filing index links above go to sec.gov.